Valuation: RenovoRx, Inc.

Market Cap 66.34M 58.89M 55.11M 49.95M 94.34M 6.4B 95.02M 662M 257M 3.26B 249M 244M 10.49B P/E 2026 *
-5.35x
P/E 2027 * -9.93x
Enterprise Value 66.34M 58.89M 55.11M 49.95M 94.34M 6.4B 95.02M 662M 257M 3.26B 249M 244M 10.49B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 5.8x
Free-Float
96.41%
Yield 2026 *
-
Yield 2027 * -
08-25 RenovoRx Publishes Pharmacokinetic and Pharmacodynamic Data Supporting Tamp Platform?s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer CI
08-24 RenovoRx, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-20 RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment CI
08-12 RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 CI
08-11 RenovoRx Achieves Full Enrollment in Phase III Tiger-Pac Trial for Locally Advanced Pancreatic Cancer CI
08-06 RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment CI
08-05 Renovorx Inc and Carti Cancer Center Announce First Commercial Clinical Use of Renovocath in Sarcoma Patient Treatment CI
06-23 RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, Jun-23-2026 12:30 PM
06-11 RenovoRx Announces Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP In Locally Advanced Pancreatic Cancer CI
06-01 RenovoRx, Inc., Q1 2026 Earnings Call, May 14, 2026
05-28 RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer RE
05-26 Renovorx Publishes Pharmacokinetic and Pharmacodynamic Sub-Study Results from Ongoing Phase III TIGeR-PaC Clinical Trial Evaluating Tamp Platform for Targeted Intra-Arterial Delivery of Gemcitabine CI
1 day-5.44%
1 week-10.32%
Current month-10.90%
1 month-41.84%
3 months+51.07%
6 months+41.84%
Current year+65.46%
1 week 1.37
Extreme 1.37
1.64
1 month 1.37
Extreme 1.37
2.34
Current year 0.77
Extreme 0.77
2.59
1 year 0.7
Extreme 0.7006
2.59
3 years 0.53
Extreme 0.5306
2.59
5 years 0.53
Extreme 0.5306
12.51
10 years 0.53
Extreme 0.5306
16.74
Manager TitleAgeSince
Chief Executive Officer 49 2014-10-26
Chief Tech/Sci/R&D Officer 60 2009-11-30
Director of Finance/CFO 71 2026-02-02
Director TitleAgeSince
Director/Board Member 82 2012-11-30
Chairman 60 2018-04-30
Director/Board Member 84 2011-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Free

Director

55,924 0.1239%
10/1/26 Free

Director

55,924 0.1239%
10/1/26 Free

Director

55,924 0.1239%
Change 5-day change 1-year change 3-year change Capi.($)
-5.44%-10.32%+5.30%+20.87% 66.34M
-1.94%-2.79%-27.07%+2.04% 173B
-1.00%-2.69%-10.86%+14.37% 113B
-2.46%+1.05%-24.91%+5.06% 109B
+1.52%+0.41%-48.13%-10.00% 74.44B
+0.46%+4.13%+4.50%+70.97% 60.1B
+3.27%+7.25%+18.14%+67.16% 51.87B
-0.20%-1.92%-6.87%-30.93% 49.21B
-2.21%-2.58%-18.34%+19.72% 41.52B
-4.04%-3.80%+24.37%-0.73% 32.79B
Average -1.20%+0.04%-8.39%+15.85% 70.51B
Weighted average by Cap. -0.91%+0.42%-16.04%+12.48%

Financials

2026 *2027 *
Net sales 3.87M 3.44M 3.22M 2.92M 5.51M 373M 5.55M 38.64M 15.03M 190M 14.54M 14.22M 612M 11.43M 10.15M 9.5M 8.61M 16.26M 1.1B 16.38M 114M 44.37M 562M 42.92M 42M 1.81B
Net income -12M -10.65M -9.97M -9.04M -17.07M -1.16B -17.19M -120M -46.57M -590M -45.05M -44.08M -1.9B -7.01M -6.22M -5.83M -5.28M -9.97M -676M -10.04M -69.97M -27.21M -345M -26.32M -25.76M -1.11B
Net Debt - -
Projected Income Statement - Annual - RenovoRx, Inc.
Logo RenovoRx, Inc.
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Employees
-
Date Price Change Volume
26-10-06 US$1.390 -5.44% 620,191
26-10-05 US$1.470 -6.96% 618,033
26-10-02 US$1.580 +1.94% 269,370
26-10-01 US$1.550 -0.64% 404,025
26-09-30 US$1.560 -0.64% 397,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - RenovoRx, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.390USD
Average target price
7.125USD
Spread / Average Target
+412.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - RenovoRx, Inc.
  1. Stock Market
  2. Stocks
  3. RNXT Stock